FOLH1 and bone neoplasm: Furthermore, we evaluated the impact of baseline PSMA-ligand PET-derived bone tumor metrics specifically on the occurrence of severe (Grade 3/4) hematologic AEs, which are particularly relevant for risk stratification in 177Lu-PSMA RLT.